Extensive knowledge of hematology and oncology research, vast capabilities and experience with feasibility studies and a large investigator network.
PPD's Phase I Clinic conducts clinical studies to determine how new medicines act in the bodies of healthy volunteers.
Get information about PPD posted on industry websites and publications.
PPD today announced that its parent company, PPD, Inc. (formerly known as Eagle Holding Company I), has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of the parent company’s common stock.
12 Nov. 2019
PPD has launched PPD’s SiteCoach, providing advanced clinical research training, coaching and support to physicians, hospitals and academic institutions that are new to clinical research.
30 Oct. 2019
PPD has been named Best CRO Provider for the second time in the last three years at the World ADC Awards.
17 Oct. 2019
PPD has been named a CSO50 Award winner for information security initiatives demonstrating outstanding business value and thought leadership.
03 Oct. 2019
PPD is expanding its bioanalytical laboratory in Richmond, Virginia, enhancing its ability to provide industry-leading capabilities to meet biopharmaceutical clients’ increasing research needs.
19 Sept. 2019
Accelerated Enrollment Solutions has acquired the clinical research site business of Bioclinica, expanding its global footprint and solidifying AES’ leadership position in patient access and site conduct.
05 Sept. 2019
Harbour BioMed and PPD announced a strategic collaboration to develop HBM’s innovative therapeutics in the fields of oncology and immunology.
27 Aug. 2019
Evidera, a business unit of PPD, has entered into an exclusive collaboration agreement with CSS, a subsidiary of SNBL, extending both organizations’ capabilities.
21 Aug. 2019
NeoGenomics and PPD announced the grand opening of a NeoGenomics oncology-focused clinical trials testing lab in the same building as the PPD Laboratories central lab in Singapore.
31 Jul. 2019
Optimal Just-in-Time, a service of PPD’s Accelerated Enrollment Solutions (AES) business unit, and Cancer Treatment Centers of America are collaborating to speed patient enrollment in oncology clinical trials.
16 Jul. 2019
Senior Manager, Corporate CommunicationsPPD
Tel: +1 919 456 4425
Manager, Corporate CommunicationsPPD
Tel: +1 919 456 6389
We want to hear from you
Register in PPD's Database
© 2019 Pharmaceutical Product Development, LLC. All rights reserved.